Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers

EJNMMI Research

Volumn 1, Issue 1, 2011, Pages 1-11

  Chatenet, David ^a,b   Cescato, Renzo ^c   Waser, Beatrice ^c   Erchegyi, Judit ^a   Rivier, Jean E ^a   Reubi, Jean Claude ^a,c  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE   (Canada)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antagonist; Breast cancer; Neuropeptide Y receptor; Oncology; Peptide receptor radionuclide therapy; Tumor imaging

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; FORSKOLIN; HETERODIMER; LYSINE; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; SCAFFOLD PROTEIN; TETRAXETAN; TETRAXETAN NEUROPEPTIDE Y1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

AMINO ACID SYNTHESIS; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; IN VITRO STUDY; ISOTOPE LABELING; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; STRUCTURE ANALYSIS;

EID: 84870859404     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-1-21     Document Type: Article

References (38)

1. Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24:389-427.
2. Maecke HR, Reubi JC: Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med 2011, 52:841-4.
3. Ginj M, Zhang H, Eisenwiener KP, Wild D, Schulz S, Rink H, Cescato R, Reubi JC, Maecke HR: New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting. Clin Cancer Res 2008, 14:2019-27.
4. Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC: DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003, 30(10):1338-47.
5. Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, Erchegyi J, Rivier J, Mäcke HR, Reubi JC: Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006, 103:16436-41.
6. Wild D, Fani M, Behe M, Brink I, Rivier J, Reubi JC, Maecke HR, Weber WA: First clinical evidence that imaging with somatostatin receptor antagonists is clinically feasible. J Nucl Med 2011.
7. Reubi JC, Gugger M, Waser B, Schaer JC: Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 2001, 61:4636-41.
8. Korner M, Reubi JC: NPY receptors in human cancer: a review of current knowledge. Peptides 2007, 28:419-25.
9. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T: XVI. International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998, 50:143-50.
10. Balasubramaniam A: Clinical potentials of neuropeptide Y family of hormones. Am J Surg 2002, 183:430-4.
11. Kamiji MM, Inui A: Neuropeptide Y receptor selective ligands in the treatment of obesity. Endocr Rev 2007, 28:664-84.
12. Korner M, Waser B, Reubi JC: Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas. Int J Cancer 2005, 115:734-41.
13. Korner M, Waser B, Reubi JC: High expression of neuropeptide y1 receptors in ewing sarcoma tumors. Clin Canc Res 2008, 14:5043-49.
14. Korner M, Reubi JC: Neuropeptide Y receptors in primary human brain tumors: overexpression in high-grade tumors. J Neuropathol Exp Neurol 2008, 67:741-49.
15. Khan IU, Beck-Sickinger AG: Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anticancer Agents Med Chem 2008, 8:186-99.
16. Langer M, Kratz F, Rothen-Rutishauser B, Wunderli-Allenspach H, Beck-Sickinger AG: Novel peptide conjugates for tumor-specific chemotherapy. J Med Chem 2001, 44:1341-48.
17. Langer M, La Bella R, Garcia-Garayoa E, Beck-Sickinger AG: 99 mTc-Labeled Neuropeptide Y Analogues as Potential Tumor Imaging Agents. Bioconjug Chem 2001, 12:1028-34.
18. Khan IU, Zwanziger D, Bohme I, Javed M, Naseer H, Hyder SW, Beck-Sickinger AG: Breast-cancer diagnosis by neuropeptide Y analogues: from synthesis to clinical application. Angew Chem Int Ed Engl 2010, 49:1155-8.
19. Reubi JC, Erchegyi J, Cescato R, Waser B, Rivier JE: Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog. Eur J Nucl Med Mol Imaging 2010, 37:1551-8.
20. Korner M, Waser B, Reubi JC: Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab Invest 2004, 84:71-80.
21. Reubi JC, Schaer JC, Waser B, Wenger S, Heppeler A, Schmitt J, Mäcke HR: Affinity profiles for human somatostatin receptor sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000, 27:273-82.
22. Erchegyi J, Cescato R, Grace CR, Waser B, Piccand V, Hoyer D, Riek R, Rivier JE, Reubi JC: Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues. J Med Chem 2009, 52:2733-46.
23. Balasubramaniam A, Dhawan VC, Mullins DE, Chance WT, Sheriff S, Guzzi M, Prabhakaran M, Parker EM: Highly selective and potent neuropeptide Y (NPY) Y1 receptor antagonists based on [Pro(30), Tyr(32), Leu(34)]NPY (28-36)-NH2 (BW1911U90). J Med Chem 2001, 44:1479-82.
24. Balasubramaniam A, Zhai W, Sheriff S, Tao Z, Chance WT, Fischer JE, Eden P, Taylor J: Bis(31/31') ([CYS(31), Trp(32), Nva(34)] NPY-(31-36): a specific NPY Y-1 receptor antagonist. J Med Chem 1996, 39:811-3.
25. Daniels AJ, Matthews JE, Slepetis RJ, Jansen M, Viveros OH, Tadepalli A, Harrington W, Heyer D, Landavazo A, Leban JJ: High-affinity neuropeptide Y receptor antagonists. Proc Natl Acad Sci USA 1995, 92: 9067-71.
26. Beck-Sickinger AG, Wieland HA, Wittneben H, Willim KD, Rudolf K, Jung G: Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations. Eur J Biochem 1994, 225:947-58.
27. Merten N, Lindner D, Rabe N, Rompler H, Morl K, Schoneberg T, Beck-Sickinger AG: Receptor subtype-specific docking of Asp6.59 with Cterminal arginine residues in Y receptor ligands. J Biol Chem 2007, 282:7543-51.
28. Leban JJ, Heyer D, Landavazo A, Matthews J, Aulabaugh A, Daniels AJ: Novel modified carboxy terminal fragments of neuropeptide Y with high affinity for Y2-type receptors and potent functional antagonism at a Y1-type receptor. J Med Chem 1995, 38:1150-7.
29. Reubi JC, Schaer JC, Wenger S, Hoeger C, Erchegyi J, Waser B, Rivier J: sst3-selective potent peptidic somatostatin receptor antagonists. Proc Natl Acad Sci USA 2000, 97:13973-78.
30. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, Reubi JC: Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008, 49:318-26.
31. Cowley DJ, Hoflack JM, Pelton JT, Saudek V: Structure of neuropeptide Y dimer in solution. Eur J Biochem 1992, 205:1099-106.
32. Daniels AJ, Heyer D, Landvazo O, Leban JK, Spaltenstein A: Neuropeptide Y antagonists 1994, WO94/00486.
33. Murase S, Yumoto N, Petukhov MG, Yoshikawa S: Acylation of the alphaamino group in neuropeptide Y(12-36) increases binding affinity for the Y2 receptor. J Biochem 1996, 119:37-41.
34. Guerin B, Dumulon-Perreault V, Tremblay MC, Ait-Mohand S, Fournier P, Dubuc C, Authier S, Bénard F: [Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging. Bioorg Med Chem Lett 2010, 20:950-3.
35. Jois SD, Balasubramaniam A: Conformation of neuropeptide Y receptor antagonists: structural implications in receptor selectivity. Peptides 2003, 24:1035-43.
36. Dinger MC, Bader JE, Kobor AD, Kretzschmar AK, Beck-Sickinger AG: Homodimerization of neuropeptide y receptors investigated by fluorescence resonance energy transfer in living cells. J Biol Chem 2003, 278:10562-71.
37. Balasubramaniam A, Sheriff S, Zhai W, Chance WT: Bis(31/31')[Cys(31), Nva (34)]NPY(27-36)-NH(2)]: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides 2002, 23:1485-90.
38. IUPAC-IUB Joint Commission on Biochemical Nomenclature: Nomenclature and symbolism for amino acids and peptides. Eur J Biochem 1984, 138:9-37.